Elucid, a closely-held medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, appointed Scott Burger as chief commercial officer.
His appointment comes as Elucid expands the commercial footprint of its PlaqueIQ technology, the only FDA-cleared plaque analysis software to identify and match CT images to patient tissue samples, simulating what a pathologist would see under a microscope.
Mr. Burger has more than 15 years of leadership experience and will lead sales, marketing, market access and customer success. He joins Elucid from CorVista Health, a non-invasive cardiac diagnostics company.
“His vast range of leadership experiences in the medical device and services space is exactly what we are looking for to take us to the next level as we increase our commercial footprint,” Blake Richards, CEO of Elucid, said in a statement. “Scott’s knowledge and track record of success will be vital for Elucid as we launch several next generation plaque and fractional flow reserve – computed tomography products in the coming months.”
